<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease refractory to standard <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-one patients that did not respond to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and to at least one <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> (cyclosporin, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) for the presence of ocular and/or <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>Eighteen patients completed the study up to 54 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Stable doses of <z:chebi fb="0" ids="8382">prednisone</z:chebi> (&lt;10 mg/day) were permitted, <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> were discontinued at least 4 weeks prior baseline visit </plain></SENT>
<SENT sid="4" pm="."><plain>The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg Infliximab every 8 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>At each visit data on clinical symptoms, response to therapy and adverse events were collected </plain></SENT>
<SENT sid="6" pm="."><plain>The primary outcome of interest was to assess the clinical efficacy (total or partial recovery) of infliximab </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary end points were to evaluate quality of life and to monitor the safety of the drug </plain></SENT>
<SENT sid="8" pm="."><plain>Eighteen patients achieved a total remission </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Infliximab was well tolerated throughout the study </plain></SENT>
<SENT sid="11" pm="."><plain>A case of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was observed within 6 months </plain></SENT>
<SENT sid="12" pm="."><plain>Minor side effects were <z:hpo ids='HP_0002315'>headache</z:hpo>, dizziness, <z:hpo ids='HP_0001649'>tachycardia</z:hpo> that regressed spontaneously and did not entail interruption </plain></SENT>
<SENT sid="13" pm="."><plain>Anti-nuclear antibodies were not detected during the period of observation </plain></SENT>
</text></document>